Illumina, Inc. $ILMN Stock Position Cut by Hsbc Holdings PLC

Hsbc Holdings PLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 11.6% in the 4th quarter, HoldingsChannel reports. The fund owned 121,245 shares of the life sciences company’s stock after selling 15,895 shares during the period. Hsbc Holdings PLC’s holdings in Illumina were worth $15,909,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in ILMN. MassMutual Private Wealth & Trust FSB grew its holdings in Illumina by 7.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,081 shares of the life sciences company’s stock worth $142,000 after acquiring an additional 79 shares during the period. HighPoint Advisor Group LLC lifted its holdings in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after acquiring an additional 80 shares during the last quarter. Toronto Dominion Bank boosted its position in shares of Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares in the last quarter. Panagora Asset Management Inc. boosted its position in shares of Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 96 shares in the last quarter. Finally, Venturi Wealth Management LLC grew its stake in shares of Illumina by 4.2% in the 4th quarter. Venturi Wealth Management LLC now owns 2,465 shares of the life sciences company’s stock worth $323,000 after purchasing an additional 99 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. JPMorgan Chase & Co. raised Illumina from a “neutral” rating to an “overweight” rating and upped their price target for the company from $125.00 to $185.00 in a report on Wednesday, June 10th. Barclays boosted their target price on Illumina from $122.00 to $145.00 and gave the stock an “underweight” rating in a research report on Wednesday. Royal Bank Of Canada initiated coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target for the company. Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective for the company in a research note on Thursday, May 14th. Finally, Citigroup raised their target price on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus target price of $143.56.

Illumina Stock Up 1.5%

ILMN stock opened at $177.65 on Friday. Illumina, Inc. has a 12-month low of $88.00 and a 12-month high of $182.84. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company has a market cap of $26.88 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 3.28 and a beta of 1.50. The company has a 50 day moving average of $148.74 and a two-hundred day moving average of $137.38.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter last year, the business posted $0.97 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 5.21 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In other Illumina news, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the transaction, the insider owned 20,953 shares in the company, valued at $3,771,540. The trade was a 2.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president directly owned 21,259 shares in the company, valued at approximately $3,456,500.81. The trade was a 3.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,003,769 shares of company stock worth $155,710,908 in the last ninety days. Company insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.